输血相关性铁过载在血液肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2017.01.017

摘要/Abstract

摘要： 输血相关性铁过载破坏机体铁稳态,从而损害重要脏器结构,导致重要脏器的功能障碍。铁过载影响患者预后,促进骨髓增生异常综合征(Myelodysplastic syndrome,MDS)向急性白血病转化,降低造血干细胞移植后患者总生存率,增加造血干细胞移植后治疗相关死亡率,并增加感染的机会。祛铁治疗可延缓骨髓增生异常综合征向急性白血病的进展,延长移植后患者的总生存期,并表现出一定的抗增殖活性。

关键词: 铁过载, 骨髓增生异常综合症, 造血干细胞移植, 预后

Abstract: Transfusion-related iron overload damage iron homeostasis of organism,which damages the structure of the vital organs and leads to the dysfunction of important organs.Iron overload affects the prognosis of the patients,which promotes myelodysplastic syndrome transformation to acute leukemia and reduces the total survival rate of patients with hematopoietic stem cell transplantation,which increases the treatment related mortality after hematopoietic stem cell transplantation and increases the chance of infection.Iron depletion therapy can delay the progression of acute leukemia and prolong the survival time of the patients with acute leukemia and show a certain anti-proliferative activity.

Key words: Transfusion-related iron overload, Myelodysplastic syndrome, Hematopoietic stem cell transplantation, Prognosis

中图分类号:

R733.7

杜雅茹, 赵艳红综述, 周晋审校. 输血相关性铁过载在血液肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(1): 78-82.

DU Yaru, ZHAO Yanhong, ZHOU Jin. The research progress in transfusion-related iron overload in hematological malignancies[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 78-82.

参考文献

1 Goldberg SL,Chen E,Corral M,et al.Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries[J].J Clin Oncol,2010,28(17):2847-2852.
2 Gattermann N,Finelli C,Della PM,et al.Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes[J].Haematologica,2012,97(9):1364-1371.
3 黄蕾,付蓉,邵宗鸿.铁过载组织损伤特点及机制研究进展[J].中华血液学杂志,2012,33(10):884-887.
4 Chiabrando D,Vinchi F,Fiorito V,et al.Heme in pathophysiology:a matter of scavenging,metabolism and trafficking across cell membranes[J].Front Pharmacol,2014,5(5):61.
5 Lawen A,Lane DJ.Mammalian iron homeostasis in health and disease:uptake,storage,transport,and molecular mechanisms of action[J].Antioxid Redox Signal,2013,18(18):2473-2507.
6 Brissot P,Deugnier Y,Guyader D,et al.Iron overload and the biliary route[J].Advances in Experimental Medicine & Biology,1994,356(356):277-283.
7 Hellstr-Lindberg E.Management of anemia associated with myelodysplastic syndrome[J].Seminars in Hematology,2005,42(2 Suppl 1):10-13.
8 Jomova K,Valko M.Advances in metal-induced oxidative stress and human disease[J].Toxicology,2011,283(2/3):65-87.
9 Zuo Y,Xiang B,Yang J,et al.Oxidative modification of caspase-9 facilitates its activation via disulfide-mediated interaction with Apaf-1[J].Cell Res,2009,19(4):449-457.
10 Telfer P.Update on survival in thalassemia major[J].Hemoglobin,2009,33(Suppl1):76-80.
11 Yang JC,Robert C,Gough SM,et al.Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome[J].Leuk Res,2014,38(1):95-102.
12 Bejar R,Stevenson K,Abdelwahab O,et al.Clinical effect of point mutations in myelodysplastic syndromes[J].N Engl J Med,2011,364(26):2496-2506.
13 Pullarkat V.Objectives of iron chelation therapy in myelodysplastic syndromes:more than meets the eye?[J].Blood,2009,114(26):5251-5255.
14 Kikuchi S,Kobune M,Iyama S,et al.Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox[J].Free Radic Biol Med,2012,53(4):643-648.
15 Badawi MA,Vickars LM,Chase JM,et al.Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome[J].Adv Hematol,2010,2010:1687-9104.
16 List AF,Baer MR,Steensma DP,et al.Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome[J].J Clin Oncol,2012,30(17):2134-2139.
17 Baldomero H,Gratwohl M,Gratwohl A,et al.The EBMT activity survey 2009:trends over the past 5 years[J].Bone Marrow Transplantation,2011,46(4):485-501.
18 Gaziev J,Sodani P,Polchi P,et al.Bone marrow transplantation in adults with thalassemia:treatment and long-term follow-up[J].Ann N Y Acad Sci,2005,1054(1):196-205.
19 Kanda J,Mizumoto C,Ichinohe T,et al.Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation[J].Bone Marrow Transplantation,2011,46(2):208-216.
20 Armand P,Kim HT,Rhodes J,et al.Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation[J].Biol Blood Marrow Transplant,2011,17(6):852-860.
21 Wermke M,Schmidt A,Middeke JM,et al.MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation[J].Clin Cancer Res,2012,18(23):6460-6468.
22 Maradei S C,Maiolino A,de Azevedo A M,et al.Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation[J].Blood,2009,114(6):1270-1275.
23 Pullarkat V,Blanchard S,Tegtmeier B,et al.Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation[J].Bone Marrow Transplantation,2008,42(12):799-805.
24 Tachibana T,Tanaka M,Takasaki H,et al.Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignancies[J].Int J Hematol,2011,93(3):368-374.
25 Guo M,Song L P,Jiang Y,et al.Hypoxia-mimetic agents desferrioxamine and cobalt chloride induce leukemic cell apoptosis through different hypoxia-inducible factor-1alpha independent mechanisms[J].Apoptosis,2006,11(1):67-77.
26 Pullarkat V,Sehgal A,Liang L,et al.Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors[J].Leuk Res,2012,36(8):966-973.
27 Roth M,Will B,Simkin G,et al.Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation[J].Blood,2012,120(2):386-394.
28 Fukushima T,Kawabata H,Nakamura T,et al.Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia[J].Anticancer Res,2011,31(5):1741-1744.
29 Yamasaki T,Terai S,Sakaida I.Deferoxamine for advanced hepatocellular carcinoma[J].N Engl J Med,2011,365(6):576-578.
30 Kaloyannidis P,Yannaki E,Sakellari I,et al.The impact of desferrioxamine postallogeneic hematopoietic cell transplantation in relapse incidence and disease-free survival:a retrospective analysis[J].Transplantation,2010,89(4):472-479.
31 Michallet M,Sobh M,Morisset S,et al.Significant impact of iron chelation after allogeneic hematopoetic stem cell transplantation on disease recurrence:potential anti-leukemic activity[J].Blood,2013,122(21):180.
32 Greenberg PL,Attar E,Bennett JM,et al.NCCN clinical practice guidelines in oncology:myelodysplastic syndromes[J].J Natl Compr Canc Netw,2011,9(1):30-56.
33 Meynard D,Babitt JL,Lin HY.The liver:conductor of systemic iron balance[J].Blood,2013,123(2):168-176.
34 Oshrine B,Lehmann LE,Duncan CN.Safety and utility of liver biopsy after pediatric hematopoietic stem cell transplantation[J].J Pediatr Hematol Oncol,2011,33(3):92-97.
35 Kikuchi S,Kobune M,Iyama S,et al.Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox[J].Free Radic Biol Med,2012,53(4):643-648.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[3]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[4]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[5]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[6]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[7]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[8]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.
[9]	杨洪波, 石洁, 叶勇, 李文成, 邓兆平. COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 52-56.
[10]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[11]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[12]	肖洪伟, 陈升, 王艳良, 苏学良. 距肛缘≤8 cm的T₁期直肠癌患者经肛门局部切除术的预后及影响因素分析[J]. 实用肿瘤学杂志, 2018, 32(6): 545-549.
[13]	王一然, 黄维, 尹蕾, 刘琳, 周晓平, 牛星鉴, 杨悦, 安巍巍, 姬宏飞. 中性粒细胞与淋巴细胞比值对宫颈癌患者同步放化疗疗效及预后判断的临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 404-409.
[14]	李美艳, 陈永学, 侯俊德. Leptin、VEGF及不同麻醉方式对子宫内膜癌患者预后生存的影响[J]. 实用肿瘤学杂志, 2018, 32(5): 426-431.
[15]	韩滕综述, 唐丽萍审校. PD-L1的表达与妇科恶性肿瘤预后关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 468-470.